• President Biden proclaims February as American Heart Month
• Annual tradition provides opportunity to focus on nationwide problem of heart and blood-vessel diseases
• HeartBeam is committed to being part of the solution for identifying, treating heart attacks

Following a decades-long tradition, President Joseph Biden issued a proclamation from the White House declaring February as American Heart Month (https://ibn.fm/6Z9Iq). This nationwide focus on heart health is fully supported by HeartBeam (NASDAQ: BEAT), a cardiac technology company dedicated to leading the way in finding effective ways to detect heart attacks earlier than ever before.

“During American Heart Month, we recommit to supporting the more than 120 million Americans living with a cardiovascular condition; advancing groundbreaking and lifesaving research; and expanding access to affordable health care, prescription drugs, and healthy lifestyles,” the White House proclamation stated. “Heart disease has long been the leading cause of death in the United States, claiming nearly 700,000 lives a year.

“Nearly half of all American adults have at least one major risk factor for cardiovascular disease,” the statement continued. “From heart attacks and strokes to high blood pressure, the threat of cardiovascular disease touches almost every family in our nation. But while heart conditions can be costly and deadly, they are also often preventable with access to affordable health care, advancements in technology and lifestyle changes.”

American Heart Month is a longstanding tradition. President Lyndon B. Johnson established the tradition when he issued Presidential Proclamation 3566 in December 1963, 10 days after Congress issued a joint resolution requesting the president to issue an annual proclamation (https://ibn.fm/v2Sv2). In announcing February 1964 as the first American Heart Month, President Johnson urged “the people of the United States to give heed to the nationwide problem of the heart and blood-vessel diseases, and to support the programs required to bring about its solution.”

HeartBeam is committed to being part of the solution for identifying and treating heart attacks.

The company has two patented products in development: HeartBeam AIMI(TM), software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately; and HeartBeam AIMIGo(TM), the first and only credit-card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection.

Noting that every 40 seconds someone in the United States has a heart attack, or myocardial infarction (“MI”), HeartBeam points out that many people second-guess their heart-attack symptoms (https://ibn.fm/FmgJa). “Unfortunately, there is no way for patients to tell if the symptoms they are experiencing are due to an MI. As a result, patients often ignore symptoms and delay seeking care, which leads to worse outcomes and increased mortality.”

HeartBeam is developing a personal, portable and easy-to-use heart-attack detection solution. People will be able to use the system anytime, anywhere to help their clinicians determine if chest pain is the result of a heart attack, leading to faster identification and treatment. “For the first time outside of a medical setting, physicians can determine with a patient-friendly device if chest pains are due to a heart attack,” the company reports.

Although HeartBeam AIMI and HeartBeam AIMIGo have not yet been cleared by the US Food and Drug Administration (“FDA”), the company is “on track with our HeartBeam AIMIGo 3D vector ECG first-generation product, which we expect will be ready for FDA submission in Q1 2023, and the anticipated FDA clearance for our HeartBeam AIMI system,” wrote HeartBeam founder and CEO Branislav Vajdic, PhD, in a recent shareholder report (https://ibn.fm/zRZA7).

“We are leveraging our strategic partnerships with multiple industry leaders to move toward production and commercialization of our products, with plans to broaden our product portfolio pipeline with smartwatch connectivity,” Vajdic continued. “Our commercial team has continued to engage in productive discussions with strategic healthcare institutions, including academic centers, regional systems, and regional community hospital systems. We enter 2023 with tremendous momentum and look forward to sharing our accomplishments in the coming year as we strive to create value for our customers, shareholders, employees, and communities.”

For more information, visit the company’s website at www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

• Coyuchi, the gold standard in sustainable luxury home goods, has not only pushed the sustainability conversation forward but also lived it in all of its operations
• Its unique market positioning has seen its net income grow by 26% YOY between 2020 and 2021, with a return customer rate of 35% over 24 months
• The company’s management is optimistic that 2023 will be a great year, with the foundations laid so far playing a pivotal role in its growth. One of the critical areas to be explored will be partnerships with retailers
• Coyuchi’s commitment to sustainability and circular design will also continue to play a role in the company’s growth in 2023. Its management is confident that its current positioning will take advantage of the growth within the global organic cotton market, allowing Coyuchi to stamp its position and continue playing a key role in its space

Coyuchi, the gold standard in sustainable luxury home goods, is entering a new phase of growth in the wake of the increasing consideration of and investment in sustainability at scale. As a company that has built its brand around offering sustainably-produced luxury organic bedding, sheets, towels, apparel, and other home goods for the environmentally conscious home, Coyuchi has not only pushed the sustainability conversation forward but also lived it through its operations.

The company’s unique market positioning has seen its net income grow by 26% year-over-year (“YOY”) between 2020 and 2021, with a return customer rate of 35% over 24 months (https://ibn.fm/OjG77). According to its management, this was contributed mainly by the company’s commitment to sustainability, being vocal about it, and actively bringing its products closer to the consumers, as evidenced by the opening of the second retail location in Palo Alto, California (https://ibn.fm/SCTES).

Circular design has also informed and shaped Coyuchi’s commitment to sustainability. As the first home textiles brand to launch a resale business in 2017, the company has come to use post-consumer waste, which is recycled into new cotton yarns for the new product. This is further accentuated by the company’s transparent approach to its operations, going beyond declaring the company’s day-to-day activities to tracing fibers to organic farms, an integral step when developing and marketing new products.

Coyuchi’s management is optimistic that 2023 will be a great year for the company. It is confident that the foundations laid down so far will contribute to the company’s growth, with one of the key areas to be explored being partnerships with retailers.

“We’re really interested in partnerships with other retailers,” noted Mockus.

“70% of bedding purchases are made through department stores. We’re an online business, and we want to show up with other retailers,” she added.

The company’s commitment to sustainability will also play an integral role in this growth, particularly with the company having pledged itself to achieve net zero emissions by 2025 and net positive emissions by 2030. With the global organic cotton market estimated to reach $6.7 billion by 2028, up from $518.7 million in 2020, Coyuchi’s management is confident that the company is well positioned to take advantage of this growth, and be an instrumental player in its space as time progresses (https://ibn.fm/SM0Hj).

For more information, visit the company’s website at www.Coyuchi.com.

NOTE TO INVESTORS: The latest news and updates relating to Coyuchi are available in the company’s newsroom at https://ibn.fm/COYU

• REZYFi is a real estate-oriented mortgage company servicing the needs of licensed and permitted cannabis companies and owners of real estate who lease to cannabis companies
• The average rate on a 30-year-fixed-rate mortgage, measured weekly, has been declining gradually since October last year, increasing the market for new and refinanced mortgages
• Mortgage refinancing can be a source of capital, presenting an important financing opportunity for business operators in the cannabis space who struggle to access money from traditional banks

In the months since the US average rate on a 30-year-fixed-rate mortgage peaked at more than 7.10% in October last year, the value has been gradually declining. According to Freddie Mac’s weekly mortgage rate survey, the average rate stood at 6.12% as of February 9, 2023, a slight increase from the 6.09% average recorded a week earlier on February 2, 2023 (https://ibn.fm/RIiPO). This general softening has had a ripple effect.

Data from the Mortgage Bankers Association (“MBA”) shows that the decrease in average mortgage rates resulted in a week-over-week increase in mortgage applications for the week ending February 3 (https://ibn.fm/Cp55x). According to the trade group, the Market Composite Index, a measure of the mortgage loan application volume, grew 7.4% on a seasonally adjusted basis and 8% on an unadjusted basis. In addition, the Refinance Index increased 18% from the previous week, while the seasonally adjusted Purchase Index rose 3% from a week earlier (https://ibn.fm/6zcDK).

To put it more concisely, both the purchase and refinance applications increased over this period. In addition, per the MBA, both showed gains in three of the four foregoing weeks because of lower rates. And with experts projecting that the downtrend will continue, the ripple may eventually turn into a large wave. Mike Fratantoni, MBA’s Chief Economist, is quoted in an ABC article as saying that the mortgage rates are expected to end the year closer to 5% rather than the current 6% (https://ibn.fm/uGNQO).

Refinancing at lower mortgage rates presents several obvious benefits to any real estate owners. It helps them lower their monthly payments. For instance, a consumer purchasing a $400,000 home at a 30-year fixed mortgage rate of 6.12% will pay roughly $290 less in monthly mortgage payments than they would have if they had purchased the home in October last year. Additionally, by taking a larger mortgage, owners can access the difference in cash (cash-out refinancing) and direct it to any purpose (https://ibn.fm/Wo4y9). For businesses, the cash-out referencing option can be a source of much-needed capital. And nowhere is this more befitting than in the cannabis space.

Operators within the cannabis industry have long struggled with access to capital in the form of mortgages and loans. This is because most traditional banks and financial institutions, which are insured by the Federal Deposit Insurance Corporation (“FDIC”), are prohibited from offering financial services or loans to cannabis companies. So, the declining average mortgage rates are a boon for business owners in this space, and companies like REZYFi are on standby to help such proprietors.

REZYFi is a growth mortgage origination and specialized financing company in the United States. It provides a variety of real estate-related first and additional mortgage-based financing and project-specific financings, primarily targeting licensed and permitted cannabis companies and owners of real estate who lease to cannabis companies. By leveraging a network of independent brokers and licensed loan officers as well as proprietary loan processing technology, REZYFi is keen on efficiently serving as many clients as possible.

Licensed in 36 states, REZYFi operates through its subsidiaries REZYFi Lending, which addresses emerging real estate-related financing opportunities, and ResMac, Inc, a traditional mortgage origination, correspondent, and servicing business.

For more information, visit the company’s website at www.REZYFi.com.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• Lexaria’s patented DehydraTECH(TM) technology improves how APIs enter the bloodstream through the promotion of healthier oral ingestion methods while also increasing the effectiveness of fat-soluble active molecules
• As a disruptive technology, its impact has been felt by other players in its space, leading Lexaria to open its doors to partnering with industry experts and implementing the technology across many fields, including licensing the technology to Fortune 100 companies
• Lexaria will continue to make its technology accessible, improving the lives of people around the world

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has, since 2016, repeatedly demonstrated the potential of its patented technology, DehydraTECH(TM). The technology improves how active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods while increasing the effectiveness of fat-soluble active molecules. With the help of this technology, Lexaria has explored potential treatment options for a variety of conditions, including hypertension, epilepsy, and even nicotine replacement.

The overall potential of DehydraTECH to be used to improve existing products or create new ones has seen its application in a growing range of consumer product formats, from topical applications to oral suspensions, registered drugs, nutraceuticals, consumer packaged goods, capsules, pills, and tablets. Furthermore, as a disruptive patented technology, its impact has been felt by other players in its space, leading to Lexaria opening its doors to partnering with Fortune 100 companies to implement the technology across many fields (https://ibn.fm/OqUtR).

Lexaria, through its licensing program, is making its technology accessible to more people, potentially improving the lives of hundreds of thousands, if not millions of people around the world. With the company having set its eyes on the commercial execution of its DehydraTECH technology for the new year, its licensing program will play a key role in achieving this end. Its management remains optimistic that, as its licensing program grows, more companies will come on board, bringing its technology closer to the masses.

Currently, Lexaria engages in strategic partnerships with third-party companies interested in exploring formulation opportunities with their specific APIs of interest. It also out-licenses its technology in exchange for up-front fees, milestone payments, and/or royalty payments, while offering dietary supplement GMP-grade intermediate formulations to corporate clients on a toll-processing basis.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Agricultural digestion produces biogas by breaking down organic matter, including livestock manure, crop residues, and food waste
• Biogas is purified to create renewable natural gas, fully compatible with existing pipeline networks
• EverGen currently owns and operates five RNG and/or organic processing facilities across Canada
• RNG produced at Fraser Valley Biogas, Net Zero Waste Abbottsford, and GrowTEC bought by large Canadian utility company via long-term offtake agreement

Agricultural digestion produces biogas by breaking down organic matter such as livestock manure, crop residues, and food waste. The biogas is then purified of water vapor, sulfide, siloxanes, and hydrogen sulfide to create renewable natural gas – an environmentally friendly alternative that is fully compatible with existing pipeline networks.

EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF) aims to advance Canada’s RNG infrastructure by building a network spanning 20+ facilities within five years. The company acquires, develops, builds, owns, and operates a portfolio of RNG waste-to-energy and related infrastructure projects on the west coast in British Columbia, and towards the east with facilities in Alberta and Ontario.

RNG is considered environmentally sustainable because it is derived from sources that otherwise would release methane into the atmosphere while decomposing. RNG production can also help increase crop yields by creating digestate – a nutrient-rich byproduct of the agricultural digestion process that can be used as a fertilizer. In addition, RNG production from waste does not consume land or other natural resources and can help protect areas by diverting waste from landfills.

Biogas demand is escalating substantially as governments worldwide shift their focus toward the use of renewable energy. Increased RNG use by gas utilities is expected to additionally catalyze growth. According to Grandview Research, the global biogas market size was valued at over $60 billion in 2021 and is expected to grow at a CAGR of 4.3% from 2022 to 2030 (https://ibn.fm/k1Xzf).

Many countries worldwide are leveraging the sustainable power of RNG, including the United States, Canada, and eighteen countries in the European Union (https://ibn.fm/fpoQD). Further, to meet emission-reduction goals, many gas utilities across North America have set targets to blend RNG into their natural gas supplies that range from 5-15%. Management at EverGen believes these shifts present a potential C$16 billion+ opportunity for RNG producers.

EverGen owns and operates five RNG and/or organic processing facilities across Canada. These include Fraser Valley Biogas, Sea to Sky Soils, and Net Zero Waste Abbottsford in British Columbia, a 67% ownership in Alberta-based GrowTEC, and a 50% stake in Ontario-based Project Radius. RNG produced at Fraser Valley Biogas, Net Zero Waste Abbottsford, and GrowTEC is bought via long-term offtake agreements by FortisBC – the largest natural gas distributor in British Columbia.

“Really, what EverGen is doing is facilitating the build of that infrastructure to take organic waste and convert it into usable RNG in the existing pipeline network,” said EverGen CEO Chase Edgelow in a recent interview (https://ibn.fm/1d2ij). “The utilities are providing 20-year offtake agreements for our projects, so this provides us a stable cashflow profile that allows us to continue to expand across the country.”

EverGen Infrastructure Corp. is an established independent renewable energy producer aiming to develop RNG infrastructure across Canada. With a focus on sustainability, the company is emerging as a leader committed to powering a net-zero future based on renewable energy sources.

For more information, visit the company’s website at www.EverGenInfra.com.

NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

Enhanced visibility: InvestorBrandNetwork (“IBN”) has a large and diverse audience, including investors, media outlets, and industry professionals. By leveraging IBN’s network, a public company can increase its visibility and reach a wider audience.

Multi-channel distribution: IBN offers multi-channel distribution of press releases, which helps to ensure that a public company’s news is delivered to the right people through the right channels. IBN’s distribution channels include email, social media, websites, and mobile apps.

Industry expertise: IBN’s team has extensive experience in the financial and investor relations industry. This expertise can help a public company to craft messaging and communicate with investors clearly and effective.

Customized campaigns: IBN can help a public company create customized campaigns that are tailored to its specific goals and objectives. This can include everything from creating press releases and social media content to managing webinars and other events.

Access to analytics: IBN provides detailed analytics that can help a public company measure the effectiveness of its campaigns. This includes information on website traffic, social media engagement, and media coverage.

Cost-effective solutions: IBN offers a range of cost-effective solutions for public companies, including press release distribution, social media marketing, and other services. This can be especially beneficial for smaller companies that may not have the resources to manage their own investor relations campaigns.

Reputation management: IBN can help a public company manage its reputation by monitoring media coverage and social media activity. This can help to identify potential issues early on and take proactive steps to address them.

Thought leadership opportunities: IBN can help a public company position itself as a thought leader in its industry by creating content that demonstrates its expertise and knowledge.

Access to a network of industry professionals: IBN has a large network of industry professionals, including analysts, brokers, and investors. This network can be leveraged to help a public company connect with potential investors and other key stakeholders.

Improved investor engagement: By working with IBN, a public company can improve its engagement with investors and other stakeholders. This can help to build trust and strengthen relationships, which can ultimately lead to increased investment and business opportunities.

All stakeholders in patient advocacy, engagement, affairs, clinical trials, access and medical affairs are welcome to this year’s Global Innovation in Patient Advocacy conference, presented by Dynamic Global Events (“DGE”). The conference promises to empower global advocacy leaders to transcend patient partnerships, building on the success of last year’s Chief Patient Officer Summit held in July 2022 in Boston, MA.

This virtual event, scheduled for March 9-10, 2023, will cover topics such as tips for how to best assess the drug access infrastructure of specific regions, how to best identify the local landscape and map out stakeholders, including government officials, health care providers, patients and caregivers, and patient groups, plus understanding the differences in patient engagement practices in varying regions of the world. Other key topics will include:

• Characterizing differences in patient engagement practices around the world
• Understanding healthcare ecosystems and drug access infrastructures in varying regions
• Strengthening collaboration with global affiliates and across functions
• Growing capabilities for sustaining relationships with patient communities from pre-clinical through post-approval

The conference will feature a wide range of distinguished speakers, such as Thomas Bols, Head Of Government And Patient Advocacy, EMEA & APAC, PTC Therapeutics, Marie-Neith De Loisy, Patient Engagement Head – France, Novartis, and Helen Allvin, Global Patient Advocacy Lead, Orion Corporation, Orion Pharma.

Each speaker will offer a wealth of information on the critical topics for the event in the allotted 45-minute sessions, making it a perfect avenue for attendees to build on their knowledge of the various areas covered.

The breadth of this conference makes it ideal for those looking to learn how leaders in global patient advocacy and engagement thrive in ever-changing dynamic environments with external and internal collaborators. With a range of virtual sessions, attendees are guaranteed a platform where they can advance their knowledge and also network with other experts and individuals in their field.

To learn more, please visit https://ibn.fm/HCaKn.

• Health oversight agencies anticipate that, during the next decade, a growing number of people living into old age will increase the need for caregiver services for patients with a decline in cognitive function and an increase in confusion
• California-based MetAlert is a pioneer in developing wearable, unobtrusive technology that helps caregivers track the whereabouts of patients with cognitive decline and who may be prone to becoming lost if they wander
• The company is also preparing to roll out an expansion of its flagship product that will have the capacity to serve as a tech hub for its product as well as other wearable health monitoring devices with which it can communicate to collect their data for medical services
• Such devices can help eliminate the need for patients to routinely visit medical offices to monitor their health data, where they may risk exposure to other people who may endanger their health, as was made clear during the height of the COVID pandemic

Last fall, the newest report on age and health of the World Health Organization (“WHO”) stated that the number of people aged 60 years and older outnumbered children younger than 5 years in 2020 and projected that between 2015 and 2050, the proportion of the world’s population over 60 years will nearly double from 12 percent to 22 percent (https://ibn.fm/16leG).

The growth of the population of people entering into old age, and the rising ratio of older populations to younger caregiving generations, has taken on new importance for societies working to manage attendant costs and other concerns.

Wearable tracking and health monitoring device developer MetAlert (OTC: MLRT) has developed its flagship technology as an accessible solution for those dealing with one area of concern — declining cognitive capability and the potential for harmful or even deadly confusion.

The Alzheimer’s Association, in a lengthy special report providing data for 2022, notes that subtle cognitive changes, such as those in memory and thinking, are often a feature of aging, and about 12 to 18 percent of people age 60 or older are currently living with mild cognitive impairment (“MCI”). These changes may be noticeable enough for a patient, family members, and friends to become aware of, but are not severe enough to hinder everyday functioning.

One in four individuals age 80 to 84 experience symptoms of MCI, according to the report, and while MCI is distinct from dementia and Alzheimer’s disease, sometimes MCI occurs as a result of the biological changes related to Alzheimer’s. The majority of MCI patients continue with no further cognitive decline or can at times revert to normal cognition, but studies estimate 10 to 15 percent of individuals with MCI due to disease rather than normal aging go on to develop dementia each year, and about one-third of them develop dementia due to Alzheimer’s disease within five years, according to the report.

“A growing number of studies indicate that the prevalence and incidence of Alzheimer’s and other dementias in the United States and other higher income Western countries may have declined in the past 25 years,” the report states (https://ibn.fm/hxH40). “(But) the total number of people with Alzheimer’s or other dementias in the United States and other high-income Western countries is expected to continue to increase dramatically because of the increase in the number of people at the oldest ages.” That is to say that, although a person’s risk of dementia at any given age may be decreasing slightly in some countries, due to better early addressing of risk factors, the total number of people with Alzheimer’s or other dementias in the United States and other high-income Western countries is expected to continue to increase dramatically because of the growing number of people at the oldest ages.

MetAlert’s pioneering GPS-enabled SmartSole shoe inserts make it possible for caregivers to track the movements of cognitive decline patients who are prone to wander and potentially become lost, using a technology that is easy to wear and unobtrusive.

This year, the company is rolling out a –Plus model that will expand the SmartSole’s capacity to interact with other medical monitoring devices, and serve as a health tech hub that collects data from those devices to share with caregivers and medical professionals.

“During COVID, we realized that a lot of our end users have more than just the ailments that we help them with in terms of a cognitive disorder,” MetAlert CEO Patrick Bertagna said in an interview broadcast recently on the company’s YouTube channel (https://ibn.fm/SuQrz). “A lot of children with autism also have epilepsy or asthma; a lot of seniors also have diabetes or other ailments.”

When COVID was extremely virulent and a vaccine wasn’t available, a trip to the doctor’s office for a checkup ran the risk of exposing patients to further harm from infection by other patients, Bertagna said, and a measure of that risk may continue to exist today.

“We needed to find out in real time how people are doing, not how they were doing three months ago when they were in the doctor’s office, and … getting them to the doctor’s office was a challenge because of external factors that they had no control over,” he said. “So if we could bring the doctor to them, in essence, through telehealth, telemedicine and by collecting a whole bunch of vital information … and doing it in real time … it would just tremendously facilitate how the caregivers are responsible for their loved ones.”

For more information, visit the company’s website at www.MetAlert.com.

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

• China currently dominates the high-value market for rare earth elements (“REE”), but growing political tensions increasingly threaten this key supply chain, limiting the potential distribution of REE for crucial high-tech applications, such as military assets, electric vehicles, wind power generation, as well as mobile phones, and many others
• Ucore’s mission includes an ESG-centered model using RapidSX technology for the refining of REE from U.S. Allied sources, including Canada, as well as Louisiana and Alaska
• The REE market was valued at $5.3 billion in 2021 and is expected to continue growing quickly, at a CAGR of over 12%, resulting in a value of approximately $9.6 billion by 2026

Recent events have brought to light serious tensions that currently exist between the U.S. and China – including the Chinese spy balloons recently shot down in U.S. airspace and China’s anger toward the U.S. for an increased military presence planned for the Philippines. China has moved to claim dominance in the South China Sea, considering the waters as its own, in direct opposition to surrounding nations, such as the Philippines, and international law. These tensions threaten to disrupt current trade relations, including the distribution of vital rare earth elements (“REE”), on which China currently has a virtual monopoly.

Rare earth elements are a set of seventeen metallic elements necessary for the operation of many high-tech devices, including electric vehicles, cellular telephones, computer hard drives, flat-screen displays, and various defense-related products. The REE market was valued at $5.3 billion in 2021 but is expected to grow at a CAGR of 12.3%, resulting in a value of $9.6 billion by 2026 (https://ibn.fm/MwByH). Rising tensions with China have created an urgency to establish North American sources for the mining and purification of these critical elements.

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a company pursuing the exploration, separation, and scalable production of REE in Canada and the U.S., is focused on becoming a leading advanced technology company that provides best-in-class metal separation products and services to the mining and mineral extraction industry. Through strategic partnerships, Ucore’s plan is to counteract China’s control of the North American REE supply chain through the near-term development of a heavy and light rare-earth processing facility in Louisiana, with subsequent additional Strategic Metals Complexes (“SMCs”), and the longer-term development of a heavy-rare-earth-element mineral-resource property at Bokan Mountain on Prince of Wales Island, Alaska.

In 2020, Ucore acquired Innovation Metals Corp. and its RapidSX separation technology platform, focused on the production of commercial-grade, separated rare earth elements at scale. The RapidSX technology combines the traditional chemistry of conventional solvent extraction (“SX”) with a new column-based platform that significantly reduces time to completion and plant footprint, as well as potentially lowering capital and operating costs. SX is the international REE industry’s standard commercial separation technology and is used by all REE producers for bulk commercial separation. The RapidSX technology significantly improves the well-established, well-understood, and proven conventional separation methods currently in use.

In addition, an integral part of Ucore’s growth plan centers around environmental, social, and governance (“ESG”) criteria, which brings vast environmental advantages to metals processing compared to the current technology in China. North America has some of the world’s highest standards for mining labor and environmental practices – with a focus on metal extraction taking place in jurisdictions where people and the environment cannot be easily exploited.

Ucore is taking action now to develop a North American critical metals supply chain to protect the manufacturing economy and the environment. These efforts are demonstrated through the company’s North American initiatives, and represent a unique opportunity for investors to support this vital need.

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• Copper demand is rising worldwide, attributed to the renewable energy market and, recently, the re-emergence of China after its lift of pandemic restrictions
• McEwen Copper’s Los Azules project is positioned to help offset some deficit that is currently being experienced due to losses recorded by Peru and Chile mines coupled with high demand
• The 2017 Preliminary Economic Assessment (“PEA”) estimated a 36-year mine life for the Los Azules Copper Project – and only covered 55% of the known copper resources to be mined
• Additional drill holes have shown strong copper mineralization extending below the initial PEA bottom, providing an additional basis for Los Azules to become an even larger and longer-lasting mine

The renewable energy market is rising, expected to grow at a CAGR of 8.4% and reach a value of nearly $2 trillion by 2030, from $881.7 billion in 2020 (https://ibn.fm/UiPag). A key component to achieving the growth of renewable energy is copper, a sector currently facing a supply deficit, which is expected by some analysts to last until 2030 due to rising demand related to renewable energy transition, as well as the ongoing political unrest in Chile and Peru. Together these two countries produce 37% of the world’s annual production of copper.  Peru, which accounts for 10% of the global copper supply, has already reported Glencore’s suspension of its Antapaccay copper mine after protestors looted and set fire to the location. Additionally, Chile, which accounts for 27% of the global supply, recorded a 7% year-on-year decline in November 2022. Goldman Sachs predicted that Chile’s copper production will continue to decline (https://ibn.fm/5DYOI).

The rising demand for copper is thus having a magnified effect on the price of this metal. Since the beginning of 2023, copper prices have risen around 10% due to its’ demand as part of the transition away from traditional fossil fuels (https://ibn.fm/XFlB2). The rise in price has also been attributed, at least in part, to China’s re-emergence from pandemic-related shutdowns. According to Rohan Reddy, director of research at Global X ETFs, “China makes up about half of all global copper demand. There’s a saying, ‘As China goes, so does copper.'”

McEwen Mining (NYSE: MUX) (TSX: MUX), an asset-rich, diversified gold and silver producer in the Americas, is positioned to help address the rising demand for copper through its subsidiary, McEwen Copper, owner of the Los Azules copper deposit in Argentina, which is believed to be the 9th largest undeveloped copper resource in the world. According to McEwen Mining and McEwen Copper, Los Azules could easily be the world’s next copper unicorn.

In a 2017 PEA, Los Azules was designed to be an open pit mine with a 36-year life. However, indications are that the project could become an even larger mine with a longer life since only 55% of the known copper resources are to be mined. Numerous drill holes have shown strong copper mineralization extending below the designed pit bottom. The average annual production for the first 13 years in the 2017 PEA expects production to average 415 million pounds of copper – the price of copper today is over $4.00 per pound.

McEwen Copper’s vision for Los Azules is to create a regenerative mine. A profitable mine with a long life that is technologically advanced and minimizes its carbon footprint and water usage. This environmental sensitivity should enhance its appeal to investors, creating a wider investor interest in the site. Following its most recent capital raise, McEwen Copper is well-funded to advance the Los Azules Project and expects the publication of an updated PEA during H1 2023.

Additionally, an IPO is planned for Q2 2023, which will provide McEwen Copper with the funds necessary to advance Los Azules from PEA stage to complete a Feasibility Study. At the same time, McEwen Mining will be strategically adjusting its ownership by way of a secondary offering in order to strengthen its treasury, fund the expansion of its gold and silver mines and reduce its debt.

For more information, visit the company’s website at www.McEwenMining.com.

NOTE TO INVESTORS: The latest news and updates relating to MUX are available in the company’s newsroom at http://ibn.fm/MUX